Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.

NCT00335166 is registered in ClinicalTrials.gov with Solvay Pharmaceuticals as lead sponsor.

NCT NCT00335166
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00335166 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients With Early Stage Parkinson's Disease.
Lead sponsor
Solvay Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2006
Completion date
February 29, 2008
Enrollment
330 (estimated)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

early stage parkinson disease